李斯文教授从“补肾活血”论治化疗后白细胞减少症经验
Professor Li Siwen’s Clinical Experience in Treating Leukopenia after Chemotherapy Based on the Principle of “Tonifying the Kidney and Promoting Blood Circulation”
DOI: 10.12677/acm.2026.1641270, PDF,    科研立项经费支持
作者: 李梦薇, 毛 蝶, 张胜雪, 张亚莎, 徐 璐, 赵子寅:云南中医药大学第一临床医学院,云南 昆明;石 颖*:云南省中医医院肿瘤科,云南 昆明
关键词: 补肾活血化疗后白细胞减少症恶性肿瘤名医经验Kidney-Tonifying and Blood-Activating Chemotherapy-Induced Leukopenia Malignant Tumors Expert Clinical Experience
摘要: 文章介绍了李斯文教授从“补肾活血”理论出发,论治化疗后白细胞减少症的临床经验。李斯文教授认为化疗后白细胞减少症的病机关键在于肾脏亏虚、血脉瘀滞,病位在骨髓;治疗上以健脾益肾为本,活血化瘀为标,通过健脾益肾、活血化瘀,保证气血生化有源,五脏得以精微物质滋养,正气得复。现总结其经验,并列举临床病案1则。
Abstract: This article presents the clinical expertise of Professor Li Siwen in treating chemotherapy-induced leukopenia based on the “Kidney-Tonifying and Blood-Activating” theory. Professor Li posits that the pathogenesis of this condition is rooted in kidney deficiency and blood stasis, with the bone marrow being the primary locus of pathology. The therapeutic approach prioritizes reinforcing the spleen and tonifying the kidneys as the fundamental strategy, while activating blood circulation and resolving stasis serve as adjunctive measures. This dual approach ensures adequate production of qi and blood, facilitates the nourishment of the five viscera with essential substances, and promotes the restoration of healthy qi. The article summarizes his clinical experience and includes one illustrative case study.
文章引用:李梦薇, 毛蝶, 张胜雪, 张亚莎, 徐璐, 赵子寅, 石颖. 李斯文教授从“补肾活血”论治化疗后白细胞减少症经验[J]. 临床医学进展, 2026, 16(4): 476-482. https://doi.org/10.12677/acm.2026.1641270

参考文献

[1] 曹梦迪, 陈万青. GLOBOCAN 2022全球癌症统计数据解读[J]. 中国医学前沿杂志(电子版), 2024, 16(6): 1-5.
[2] Tewari, D., Rawat, P. and Singh, P.K. (2019) Adverse Drug Reactions of Anticancer Drugs Derived from Natural Sources. Food and Chemical Toxicology, 123, 522-535. [Google Scholar] [CrossRef] [PubMed]
[3] Biswal, S. and Mehta, R. (2018) Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study. Indian Journal of Dermatology, 63, 41-46. [Google Scholar] [CrossRef] [PubMed]
[4] 陈恒, 孙吉, 何鸽飞, 等. 196份抗肿瘤药物引起的严重不良反应报告表的分析[J]. 肿瘤药学, 2017, 7(5): 632-635+640.
[5] 石远凯. 临床肿瘤内科手册[M]. 北京: 人民卫生出版社, 2015.
[6] 范奎, 代良敏, 伍振峰, 等. 放化疗所致骨髓抑制的研究进展[J]. 中华中医药杂志, 2017, 32(1): 210-214.
[7] 尤翠萍, 杨梦静, 宋康乐, 等. 白细胞减少症的中医治疗概述[J]. 中医临床研究, 2023, 15(36): 45-48.
[8] 中国中西医结合学会血液病专业委员会. 肿瘤放化疗后白细胞减少症中西医结合治疗专家共识(2022年版) [J]. 中华肿瘤防治杂志, 2022, 29(23): 1641-1646+1652.
[9] 曾巧玲, 宋益青, 钟欢, 等. 中医药治疗化疗后骨髓抑制的研究进展[J]. 医学信息, 2025, 38(6): 182-185.
[10] 王清任. 医林改错[M]. 李天德, 张学文, 整理. 北京: 人民卫生出版社, 2005.
[11] 方旭鹏, 方丹, 王薇, 等. 中医药治疗恶性肿瘤化疗后白细胞降低的研究进展[J]. 世界科 学技术-中医药现代化, 2022, 24(7): 2539-2544.
[12] 胡圣涓, 杨婕, 孙韬. 从《金匮要略》探讨骨髓抑制的中医辨治[J]. 陕西中医, 2023, 44(7): 925-928.
[13] 史经龙, 谢旖阳, 梁鸿彬, 等. 基于“肝肾同源”理论探讨化疗后骨髓抑制的发病机制[J]. 广西中医药大学学报, 2025, 28(1): 45-48.
[14] 钱宇骁, 黄晓华, 石颖, 等. “因虚致瘀”论治原发性血小板增多症疾病后期思路探析[J]. 天津中医药, 2025, 42(9): 1132-1136.
[15] 朱淼, 周天, 刘秀娟, 等. 从血瘀论治化疗所致免疫抑制的思路创新[J]. 环球中医药, 2025, 18(5): 1004-1009.
[16] [清]张景岳. 景岳全书[M]. 北京: 中国中医药出版社, 2012: 97.
[17] 李可馨, 曹勇. 从健脾补肾化瘀法探析化疗后骨髓抑制的治疗[J]. 中国中医基础医学杂志, 2012, 18(4): 410-411.
[18] 戴欣, 李慧杰, 齐元富. 齐元富调和阴阳法治疗放化疗致白细胞减少经验[J]. 山东中医杂志, 2014, 33(7): 594-595.
[19] 唐宗海. 血证论[M]. 彭荣琛, 齐玲玲, 点评. 北京: 中国医药科技出版社, 2020: 7, 28, 30, 96.